首页> 外国专利> MEDICAL TREATMENT COMPRISING ENTERAL ADMINISTRATION OF EDARAVONE

MEDICAL TREATMENT COMPRISING ENTERAL ADMINISTRATION OF EDARAVONE

机译:包含伊达拉奉的肠内给药的医学治疗

摘要

A solid water-dispersible pharmaceutical composition for use in the treatment of a disease is disclosed. The treatment comprises dispersing the pharmaceutical composition into an aqueous liquid to produce an enterally administrable liquid containing at least 0.5 grams of the pharmaceutical composition and at least 0.3 g/l of edaravone, followed by enterally administering the enterally administrable liquid to a human patient in an amount providing a dose of 30-300 mg edaravone. The pharmaceutical composition comprises 2-50 wt. % of 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone) and 3-50 wt. % of a water soluble alkalizing agent. This solid edaravone containing composition can easily be dispersed in aqueous liquid to prepare an aqueous edaravone solution that can be ingested by a patient. The solid composition of the present invention offers the advantage that edaravone dissolves very rapidly when the composition is introduced into water and that the enterally administrable liquid so obtained has high oral bioavailability.
机译:公开了用于治疗疾病的固体水分散性药物组合物。该治疗包括将药物组合物分散在水性液体中以产生包含至少0.5克药物组合物和至少0.3g / l依达拉奉的肠内可给药液体,然后将肠内可给药液体对人类患者进行肠内给药。提供30-300毫克依达拉奉的剂量。药物组合物包含2-50重量%。 3-甲基-1-苯基-2-吡唑啉-5-酮(依达拉奉)的%和3-50重量%。 %的水溶性碱化剂。可以将这种包含固体依达拉奉的组合物容易地分散在水性液体中,以制备可以被患者摄取的依达拉奉水溶液。本发明的固体组合物具有以下优点:当将组合物引入水中时,依达拉奉非常迅速地溶解,并且由此获得的肠内可给药液体具有高的口服生物利用度。

著录项

  • 公开/公告号EP3570819A1

    专利类型

  • 公开/公告日2019-11-27

    原文格式PDF

  • 申请/专利权人 TREEWAY TW001 B.V.;

    申请/专利号EP20170737775

  • 发明设计人 MOOLENAAR SYTSKE HYKE;

    申请日2017-07-06

  • 分类号A61K9/14;A61K9/16;A61K31/4152;A61K47/02;A61K47/18;A61K9/08;

  • 国家 EP

  • 入库时间 2022-08-21 11:38:13

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号